News | May 30, 2024
Merck inks MoU with KAIST to advance scientific collaboration
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Greg was also central to the planning, design, and construction of this facility
These abstracts report on the company's three lead drug candidates, including olverembatinib
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Establishing Asymchem’s first manufacturing footprint in Europe
Subscribe To Our Newsletter & Stay Updated
